BioCentury
ARTICLE | Company News

Plethora genitourinary news

March 4, 2013 8:00 AM UTC

Plethora said it will no longer finance its marketing subsidiary The Urology Co. to reduce operating costs and focus its efforts on the approval and commercialization of PSD502. While revenues have grown since Plethora founded the subsidiary in 2009, the company said it continues to incur losses. After a strategic review of the subsidiary, Plethora concluded that it could not cut the cost base to drive profitability in the short term and has not been able to find a buyer. Last June, Plethora submitted an MAA to EMA for PSD502, a topical analgesic spray containing lidocaine and prilocaine, to treat premature ejaculation. The company could not be reached for details (see BioCentury, Jul 16, 2012). ...